RET activation inhibits doxorubicin-induced apoptosis in SK-N-MC cells

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2019-2025

  Skinner, Michael A ^a   Lackey, Karen E ^b   Freemerman, Alex J ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Doxorubicin; MAPK pathway; Medullary thyroid cancer; RET

Indexed keywords

DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; NEURAL CREST CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; FLAVONOIDS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION;

EID: 49049097906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P and Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Gen 2: 851-856, 1993.
2. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A and Ponder PAJ: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460, 1993.
3. Carlson KM, Dou S, Chi D, Scavarda N, Toshima T, Jackson CE, Wells SA, Jr, Goodfellow PJ and Donis-Keller H: Single missense mutation in the tyrosine kinase domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Nat Acad Sci 91: 1579-1583, 1994.
4. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagon T, Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM and Buys CHCM: A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375-376, 1994.
5. Eng C, Smith DP, Mulligan LM, Nagal MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunacliffe A and Ponder BAJ: Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Gen 3: 237-241, 1994.
6. Le HN and Norton JA: Perspective on RET proto-oncogene and thyroid cancer. Cancer J 6: 50-57, 2000.
7. Jhiang SM: The RET proto-oncogene in human cancers. Oncogene 19: 5590-5597, 2000.
8. Santoro M, Melillo RM, Carlomagno F, Fusco A and Vecchio G: Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963: 116-121, 2002.
9. Moley JF and Fialkowski EA: Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31: 946-956, 2007.
10. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G and Fusco A: Molecular characterization of RET/PTC3: a novel rearranged version of the RET proto-oncogene in a human thyroid papillary thyroid carcinoma. Oncogene 9: 509-516, 1994.
11. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G and Pierotti MA: Frequent activation of RET protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54: 2979-2985, 1994.
12. Kwok JB, Gardner E, Warner JP, Ponder BA and Mulligan LM: Structural analysis of the human RET proto-oncogene using exon trapping. Oncogene 8: 2575-2582, 1993.
13. Tahira T, Ishizaka Y, Itoh F, Sugimura T and Nagao M: Characterization of RET proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 5: 97-102, 1990.
14. Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Henderson CE, Phillips H and Johnson EM Jr: Persephin, a novel neurotrophic factor related to GDNF and neuturin. Neuron 20: 245-253, 1998.
15. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE and Evans DB: RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15: 531-544, 2005.
16. Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J and Johnson EM Jr: The long and short isoforms of Ret function as independent signaling complexes. J Biol Chem 277: 34618-34625, 2002.
17. Mason I: The RET receptor tyrosine kinase: activation, signalling and significance in neural development and disease. Pharm Acta Helv 74: 261-264, 2000.
18. Takahashi M: The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12: 361-373, 2001.
19. Saarma M: GDNF recruits the signaling crew into lipid rafts. Trends Neurosci 24: 427-429, 2001.
20. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG and Pierotti MA: Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 17: 1079-1087, 1998.
21. 2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16: 2435-2445, 1998.
22. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R and Kruijer W: MEN2A-RET-induced cellular transformation by activation of STATS. Oncogene 20: 5350-5358, 2001.
23. Melillo RM, Barone MV, Lupoli G, Cirafici AM, Carlomagno F, Visconti R, Matoskova B, Di Fiore PP, Vecchio G, Fusco A and Santoro M: Ret-mediated mitogenesis requires Src kinase activity. Cancer Res 59: 1120-1126, 1999.
24. van Weering DH and Bos JL: Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 154: 271-281, 1998.
25. Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH, Yu DY and Shong M: Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol 17: 1155-1166, 2003.
26. Bhattacharyya N: A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 128: 115-123, 2003.
27. Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R and Bulkley GB: Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 227: 887-895, 1998.
28. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
29. Pandit SD, O'Hare T, Donis-Keller H and Pike LJ: Functional characterization of an epidermal growth factor receptor/RET chimera. J Biol Chem 272: 2199-2206, 1997.
30. van Weering DH, Medema JP, van Puijenbroek A, Burgering BM, Baas PD and Bos JL: Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 11: 2207-2214, 1995.
31. van Weering DH and Bos JL: Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J Biol Chem 272: 249-254, 1997.
32. van Puijenbroek AA, van Weering DH, van den Brink CE, Bos JL, van der Saag PT, de Laat SW and den Hertog J: Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation. Oncogene 14: 1147-1157, 1997.
33. Dunn T, Praissman L, Hagag N and Viola MV: ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet Cytogenet 76: 19-22, 1994.
34. Biedler JL, Helson L and Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33: 2643-2652, 1973.
35. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C and Schlumberger M: Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 83: 715-718, 2000.
36. Robinett G, Freemerman AJ, Skinner MA, Shewchuk L and Lackey K: The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors. Bioorg Med Chem Lett 17: 5886-5893, 2007.
37. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A and Martelli AM: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722, 2008.
38. Munoz J, Lazcoz P, Inda MM, Nistal M, Pestana A, Encio IJ and Castresana JS: Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer 109: 673-679, 2004.
39. Hill MM and Hemmings BA: Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther 93: 243-251, 2002.
40. Lawlor MA and Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001.
41. Parcellier A, Tintignac LA, Zhuravleva E and Hemmings BA: PKB and the mitochondria: AKTing on apoptosis. Cell Signal 20: 21-30, 2008.
42. Sale EM and Sale GJ: Protein kinase B: signalling roles and therapeutic targeting. Cell Mol Life Sci 65: 113-127, 2008.
43. Mograbi B, Bocciardi R, Bourget I, Busca R, Rochet N, Farahi-Far D, Juhel T and Rossi B: Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells. J Biol Chem 276: 45307-45319, 2001.
44. De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN and Santoro M: Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 60: 3727-3731, 2000.
45. Baki L, Neve RL, Shao Z, Shioi J, Georgakopoulos A and Robakis NK: Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J Neurosci 28: 483-490, 2008.